Pure dysgerminoma of the ovary 35 years on: A single institutional experience

Gynecologic Oncology

Volumn 117, Issue 1, 2010, Pages 23-26

  Vicus, Danielle ^a   Beiner, Mario E ^a   Klachook, Shany ^a   Le, Lisa W ^b   Laframboise, Stephane ^a   Mackay, Helen ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Ovarian dysgerminoma; Ovarian germ cell tumor

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; MELPHALAN; VINCRISTINE;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CYSTECTOMY; DYSGERMINOMA; EXPERIENCE; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; LIVE BIRTH; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVARIECTOMY; PATIENT IDENTIFICATION; PREGNANCY; PRIORITY JOURNAL; REPRODUCTION; RETROSPECTIVE STUDY; SCHOOL CHILD; TUMOR RECURRENCE;

ADOLESCENT; ADULT; CHILD; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DYSGERMINOMA; FEMALE; FERTILITY; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949311447     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.12.024     Document Type: Article

References (21)

1. Thomas G.M., Dembo A.J., Hacker N.F., and DePetrillo A.D. Current therapy for dysgerminoma of the ovary. Obstet. Gynecol. 70 (1987) 268-275
2. Quirk J.T., and Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol. Oncol. 97 (2005) 519-523
3. De Palo G., Pilotti S., Kenda R., Ratti E., Musumeci R., Mangioni C., et al. Natural history of dysgerminoma. Am. J. Obstet. Gynecol. 143 (1982) 799-807
4. Dark G.G., Bower M., Newlands E.S., Paradinas F., and Rustin G.J. Surveillance policy for stage I ovarian germ cell tumors. J. Clin. Oncol. 15 (1997) 620-624
5. Gershenson D.M. Fertility-sparing surgery for malignancies in women. J. Natl. Cancer Inst. Monogr. (2005) 43-47
6. Brewer M., Gershenson D.M., Herzog C.E., Mitchell M.F., Silva E.G., and Wharton J.T. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J. Clin. Oncol. 17 (1999) 2670-2675
7. Patterson D.M., and Rustin G.J. Controversies in the management of germ cell tumours of the ovary. Curr. Opin. Oncol. 18 (2006) 500-506
8. Smith H.O., Berwick M., Verschraegen C.F., Wiggins C., Lansing L., Muller C.Y., et al. Incidence and survival rates for female malignant germ cell tumors. Obstet. Gynecol. 107 (2006) 1075-1085
9. Zanetta G., Bonazzi C., Cantu M., Binidagger S., Locatelli A., Bratina G., et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J. Clin. Oncol. 19 (2001) 1015-1020
10. Patterson D.M., Murugaesu N., Holden L., Seckl M.J., and Rustin G.J. A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int. J. Gynecol. Cancer 18 (2008) 43-50
11. Kumar S., Shah J.P., Bryant C.S., Imudia A.N., Cote M.L., Ali-Fehmi R., et al. The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol. Oncol. 110 (2008) 125-132
12. Zagars G.K., Ballo M.T., Lee A.K., and Strom S.S. Mortality after cure of testicular seminoma. J. Clin. Oncol. 22 (2004) 640-647
13. Huddart R.A., Norman A., Shahidi M., Horwich A., Coward D., Nicholls J., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 21 (2003) 1513-1523
14. Travis L.B., Fossa S.D., Schonfeld S.J., McMaster M.L., Lynch C.F., Storm H., et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J. Natl. Cancer Inst. 97 (2005) 1354-1365
15. National Comprehensive Cancer Network (NCCN) Clinical Practical Guidelines in Oncology. Testicular Cancer. http://www.nccn.org/professionals/physicians_gls/PDF/testicular.pdf. 2009.
16. Casey A.C., Bhodauria S., Shapter A., Nieberg R., Berek J.S., and Farias-Eisner R. Dysgerminoma: the role of conservative surgery. Gynecol. Oncol. 63 (1996) 352-357
17. Susnerwala S.S., Pande S.C., Shrivastava S.K., and Dinshaw K.A. Dysgerminoma of the ovary: review of 27 cases. J. Surg. Oncol. 46 (1991) 43-47
18. Gershenson D.M., Morris M., Cangir A., Kavanagh J.J., Stringer C.A., Edwards C.L., et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J. Clin. Oncol. 8 (1990) 715-720
19. Jeyakumar A., Cabeza R., and Hindenburg A. Late recurrence in ovarian dysgerminoma with successful response to standard adjuvant chemotherapy: a case report and review of the literature. Gynecol. Oncol. 81 (2001) 314-317
20. Gershenson D.M., Miller A.M., Champion V.L., Monahan P.O., Zhao Q., Cella D., et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (2007) 2792-2797
21. Tangir J., Zelterman D., Ma W., and Schwartz P.E. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet. Gynecol. 101 (2003) 251-257